R L Piekarz
Affiliation: National Institutes of Health
- Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case reportR L Piekarz
Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Blood 98:2865-8. 2001..Sézary cells isolated from patients after treatment had increased histone acetylation. These results suggest that inhibition of HDAC is a novel and potentially effective therapy for patients with T-cell lymphoma...
- Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaRichard L Piekarz
Departmentof Health and Human Services, Center for Cancer Researchand Cancer Therapy EvaluationProgram, National Cancer Institute, National Institutes of Health, Bethesda, USA
J Clin Oncol 27:5410-7. 2009..The median duration of response was 13.7 months. CONCLUSION The histone deacetylase inhibitor romidepsin has single-agent clinical activity with significant and durable responses in patients with CTCL...
- Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapyRichard L Piekarz
Molecular Therapeutic Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1903, USA
Cancer J 13:30-9. 2007..In this review, we discuss clinical data gathered to date, combination therapies designed to increase efficacy, and toxicities attributed to this new class of agents...
- Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphomaRichard L Piekarz
Center for Cancer Research and Cancer Therapeutics Evaluation Program, National Cancer Institute and National Heart Lung and Blood Institute, NIH, Bethesda, Maryland 20892 1903, USA
Clin Cancer Res 12:3762-73. 2006....
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaRichard L Piekarz
Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health DHHS, 6130 Executive Blvd, Rockville, MD 20852, USA
Blood 117:5827-34. 2011..The histone deacetylase inhibitor romidepsin has single agent clinical activity associated with durable responses in patients with relapsed PTCL...
- T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistanceRichard L Piekarz
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute NIH, MSC 1903, 10 Center Drive, Building 10 Room 12C103, Bethesda, MD 20892 1903, USA
Blood 103:4636-43. 2004..These studies confirm the activity of depsipeptide in a T-cell lymphoma model and suggest a general sensitivity of T-cell lymphoma to histone deacetylase inhibitors, an emerging new class of anticancer agents...
- Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)Robert W Robey
Cancer Therapeutics Branch, Center for Cancer Research, NIH, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 12:1547-55. 2006..These studies suggest that depsipeptide induces its own mechanism of resistance and thus provide a basis for clinical trials evaluating depsipeptide in combination with a Pgp inhibitor...
- New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapiesKieron Dunleavy
Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 1868, USA
Clin Cancer Res 16:5608-17. 2010..In this respect, there is a need for new approaches in these diseases, and this review focuses on and explores recent experience with novel therapies in PTCL...
- Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphomaSusan E Bates
Medical Oncology Branch, National Institutes of Health, Bethesda, MD 20892, USA
Br J Haematol 148:256-67. 2010....
- Histone deacetylase inhibitors in combinations: will the preclinical promises be kept?Susan E Bates
Molecular Therapeutics Section, Medical Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
Cancer J 13:80-3. 2007
- Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphomaSukyung Woo
Clinical Pharmacology Program, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 15:1496-503. 2009..The objective of this study was to evaluate the effect of demographic, clinical, and pharmacogenetic covariates on the pharmacokinetics of romidepsin in patients with T-cell lymphoma...
- Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometryKyunghwa Hwang
Clinical Pharmacology Research Core, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
J Chromatogr B Analyt Technol Biomed Life Sci 809:81-6. 2004..The values for precision and accuracy were always < or =7.88% and <3.33% relative error, respectively. The method was successfully applied to examine the pharmacokinetics of FK228 in a cancer patient...
- Epigenetic modifiers: basic understanding and clinical developmentRichard L Piekarz
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 15:3918-26. 2009..This issue of CCR Focus is dedicated to understanding the clinical and translational aspects of epigenetics research...
- Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasmsVictor Sandor
McGill University, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2
Clin Cancer Res 8:718-28. 2002..Biologically active serum concentrations were achieved, and 1 patient obtained a partial response. The recommended Phase II dose is 17.8 mg/m(2) administered on day 1 and 5 of a 21-day cycle...
- Effect of a histone deacetylase inhibitor on human cardiac massYukitaka Shizukuda
Cardiovasc Drugs Ther 19:89-90. 2005
- Challenges of evaluating the cardiac effects of anticancer agentsSusan E Bates
Clin Cancer Res 12:3871-4. 2006